Ranbaxy gets 180 days of exclusivity for generic Aricept

09/21/2010 | Bloomberg

Ranbaxy Laboratories gained exclusive rights to sell a generic version of Eisai's Alzheimer's drug Aricept. The FDA said Teva Pharmaceutical Industries, which has approval to sell the drug, must wait 180 days before competing with Ranbaxy.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ